Michael Raphael Tadross

Assistant Professor of Biomedical Engineering

Dr. Tadross' lab develops technologies to rapidly deliver drugs to genetically defined subsets of cells in the brain. By using these reagents in mouse models of neuropsychiatric disease, his group is mapping how specific receptors on defined cells and synapses in the brain give rise to diverse neural computations and behaviors.  The approach leverages drugs currently in use to treat human neuropsychiatric disease, facilitating clinically relevant interpretation of the mapping effort.

He received his B.S. degree in Electrical & Computer Engineering at Rutgers University, an M.D.-Ph.D. degree in Biomedical Engineering at the Johns Hopkins School of Medicine, and completed his postdoctoral study in Cellular Neuroscience at Stanford University. He began his independent research program as a fellow at the HHMI Janelia Research Campus.

Appointments and Affiliations

  • Assistant Professor of Biomedical Engineering
  • Assistant Professor in Neurobiology

Contact Information

  • Email Address: michael.tadross@duke.edu
  • Websites:


  • Ph.D. Johns Hopkins University, 2009
  • M.D. Johns Hopkins University, 2009

Research Interests

Our goal is to bridge the gap between the study of brain as a computational device and the search for novel neuropathological treatments. We develop technologies to manipulate molecules, cells, and synapses in the brain, and deploy these reagents in mouse models of disease.

Courses Taught

  • BME 791: Graduate Independent Study
  • BME 590: Special Topics in Biomedical Engineering
  • BME 493: Projects in Biomedical Engineering (GE)
  • BME 244L: Quantitative Physiology with Biostatistical Applications
  • BME 244L9: Quantitative Physiology with Biostatistical Applications

In the News

Representative Publications

  • Shields, Brenda C., Elizabeth Kahuno, Charles Kim, Pierre F. Apostolides, Jennifer Brown, Sarah Lindo, Brett D. Mensh, Joshua T. Dudman, Luke D. Lavis, and Michael R. Tadross. “Deconstructing behavioral neuropharmacology with cellular specificity.” Science (New York, N.Y.) 356, no. 6333 (April 2017): eaaj2161. https://doi.org/10.1126/science.aaj2161.